Camlin Fine Sciences reported a consolidated net profit of ₹23.54 crore for FY26, a significant drop from ₹216.04 crore EBITDA in FY25. Despite a 5.8% revenue increase to ₹1,723.31 crore, the company faced liquidity stress and a credit rating downgrade.
Camlin Fine Sciences FY26 Results: Revenue Up, Profit Compressed Amidst Challenges
Consolidated Revenue: ₹1,723.31 crore Consolidated Net Profit: ₹23.54 crore Reader Takeaway: Revenue growth is positive, but sharp EBITDA fall and liquidity issues are key concerns. ## What just happened Camlin Fine Sciences reported a consolidated revenue of ₹1,723.31 crore for the fiscal year ending March 31, 2026, an increase of 5.8% from ₹1,628.69 crore in the previous year. However, consolidated EBITDA saw a sharp decline of 50.5%, falling to ₹106.88 crore from ₹216.04 crore. The company posted a consolidated net profit of ₹23.54 crore. ## Why this matters The revenue growth indicates sustained demand for its products, but the significant drop in EBITDA highlights pressure on profitability, likely due to external factors. The net profit figure, when compared to the previous year's EBITDA, suggests a challenging operational and financial year. A credit rating downgrade to IND BBB- (long-term) could increase future borrowing costs. ## The backstory The company operates across four verticals: Specialty Ingredients, Aroma Ingredients, Performance Chemicals, and Health & Wellness. Specialty Ingredients is its largest segment. Camlin Fine Sciences has been navigating global demand slowdowns, US tariff uncertainties, and competitive pressures. In line with its strategy, it has been exiting loss-making entities and acquired a majority stake in Vinpai S.A. to strengthen its natural ingredients portfolio. ## What changes now The acquisition of an 83.82% stake in Vinpai S.A. by March 31, 2026, signals a strategic shift towards natural and clean-label ingredients. The company is also rationalizing its business, including liquidating CFS Europe S.p.A. and closing its Chinese JV, to improve efficiency. ## Risks to watch Key risks include acknowledged liquidity stress and pressure on trade payables. The downgrade in credit ratings to IND BBB- (long-term) and IND A3 (short-term) could impact financing. Geopolitical risks, such as the Middle East conflict and US tariffs on aroma products, pose external threats. Exceptional items totaling ₹25.46 crore included provisions for loan receivables, acquisition costs, and fire incident losses. ## Peer comparison While specific peer financial data for the same period isn't provided in the filing, the company's performance is occurring in a challenging chemical industry environment affected by global economic factors and trade policies. ## Context metrics (time-bound) * **Consolidated Revenue (FY26):** ₹1,723.31 crore (vs. ₹1,628.69 crore in FY25, +5.8%) * **Consolidated EBITDA (FY26):** ₹106.88 crore (vs. ₹216.04 crore in FY25, -50.5%) * **Consolidated Net Profit (FY26):** ₹23.54 crore * **Vinpai S.A. Stake:** 83.82% acquired by March 31, 2026 * **Credit Rating (Long-term):** Downgraded to IND BBB- ## What to track next Investors should monitor the company's working capital management, the integration and performance of the Vinpai S.A. acquisition, the success of portfolio rationalization, and its ability to mitigate geopolitical and tariff-related risks.
